COVID-19 and investment
Despite testing economic conditions, many companies are still looking for opportunities to invest and grow.
While the economic impact of COVID-19 is significant and still unfolding, moves have been made to give companies confidence to continue with plans to invest. These include temporary measures by the Australian Securities Exchange to facilitate capital raising and changes to the foreign investment review framework designed to protect the national interest.
M&A due diligence in the time of COVID-19: What are the ‘hangover’ risks in corporate transactions?
M&A activity continues despite COVID-19, and the changing circumstances may be providing opportunities for buyers. However, measures taken to keep businesses alive during this time may leave you with a nasty hangover post-acquisition.
ASX and ASIC introduce new temporary rules to facilitate capital raising
The Australian Securities Exchange has recently introduced temporary changes to its rules to facilitate emergency capital raisings against the current backdrop of the COVID-19 pandemic. Our Equity Capital Markets team outlines the changes.
Foreign Investment Review Board – Response to COVID-19
The Treasurer of Australia, The Hon Josh Frydenberg MP, announced on 29 March 2020 temporary changes to the foreign investment review framework, designed to protect Australia’s national interest.
Foreign Investment Review Board (FIRB) – COVID-19 changes and impact on capital raising and M&A
The Commonwealth Government announced temporary changes to the foreign investment review framework, designed to protect Australia’s national interest during the COVID-19 crisis. Whilst these temporary measures are in place, Australian companies (particularly small cap companies) looking to firm up additional funding from foreign investors or vendors seeking to sell Australian businesses or companies to foreign investors, are now more likely to require FIRB approval before these investments or acquisitions can take place.
Year-end earnings surprises and continuous disclosure: COVID-19 impact
With the financial year end (or half year) looming for many companies and the impact of COVID-19 over the last few months becoming clearer, ASX listed companies need to think carefully about their market disclosure obligations.
Full Court finds Swiss-style claims invalid – hypothesis as prior art and obviousness of invention
By Ben Miller & Sophie Vo
Clarifies the law on the construction, infringement and novelty of “Swiss-style” patent claims in Mylan v Sun Pharma.
Cautionary tales from the advertising of therapeutic goods during the COVID 19 pandemic
By Angela Wood & Sophie Vo
The active enforcement of the therapeutic goods advertising framework during the COVID-19 pandemic.
Optical Superstores: what does it mean for healthcare and allied health practices?
Implications on commercial arrangements in healthcare involving revenue sharing.
Competition law issues in the merger of Mylan and Pfizer’s Upjohn division
By Steven Tang & Oliver Wahlstrom
The competition law issues arising in the merger of Mylan and Pfizer’s Upjohn division.